Barbara Willvonseder1, Fabian Stögbauer1, Katja Steiger1,2, Moritz Jesinghaus1,2,3, Peer-Hendrik Kuhn1, Christine Brambs4, Jutta Engel5, Holger Bronger4, Georg Philipp Schmidt4, Bernhard Haller6, Wilko Weichert1,2, Gisela Keller1, Aurelia Noske1, Nicole Pfarr1, Melanie Boxberg7,8. 1. Institute of Pathology, Technical University Munich, Trogerstrasse 18, 81675, Munich, Germany. 2. German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. 3. German Cancer Consortium (DKTK), Partner Site Munich, Institute for Translational Cancer Research, Munich, Germany. 4. Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany. 5. Munich Cancer Registry, Institute for Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilians-University (LMU), Munich, Germany. 6. Institute for Epidemiology and Statistics, Technical University Munich, Munich, Germany. 7. Institute of Pathology, Technical University Munich, Trogerstrasse 18, 81675, Munich, Germany. Melanie.Boxberg@tum.de. 8. German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. Melanie.Boxberg@tum.de.
Abstract
OBJECTIVE: POLE-mutant, microsatellite-instable (MSI), p53-mutant and non-specific molecular profile (NSMP) are TCGA-defined molecular subgroups of endometrial cancer (EC). Hypothesizing that morphology and tumor immunology might differ depending on molecular background concerning composition and prognostic impact, we aimed to comprehensively interconnect morphologic, immunologic and molecular data. METHODS: TCGA-defined molecular groups were determined by immunohistochemistry and sequencing in n = 142 endometrioid EC. WHO-defined histopathological grading was performed. The immunologic microenvironment (iTME) was characterised by the quantification of intraepithelial and stromal populations of tumor-infiltrating lymphocytes (TIL: overall T-cells; T-Killer cells; regulatory T-cells (Treg)). Immunologic parameters were correlated with WHO-grading, TCGA-subgroups and prognosis. RESULTS: High density TIL were significantly more frequent in high-grade (G3) compared to low-grade (G1/2) EC in the whole cohort and in the subgroup of POLE-wildtype-/microsatellite-stable-EC. MSI was associated with high-level TIL-infiltration when taking into account the type of mismatch repair defect (MLH1/PMS2; MSH2/MSH6). Prognostic impact of biomarkers depended on molecular subgroups: In p53-mutant EC, Treg were independently prognostic, in NSMP, the unique independently prognostic biomarker was WHO-grading. CONCLUSIONS: EC morphology and immunology differ depending on genetics. Our study delineated two molecularly distinct subgroups of immunogenic EC characterized by high-density TIL-infiltration: MSI EC and high-grade POLE-wildtype/microsatellite-stable-EC. Prognostic impact of TIL-populations relied on TCGA-subgroups indicating specific roles for TIL depending on molecular background. In NSMP, histopathological grading was the only prognostic biomarker demonstrating the relevance of WHO-grading in an era of molecular subtyping.
OBJECTIVE: POLE-mutant, microsatellite-instable (MSI), p53-mutant and non-specific molecular profile (NSMP) are TCGA-defined molecular subgroups of endometrial cancer (EC). Hypothesizing that morphology and tumor immunology might differ depending on molecular background concerning composition and prognostic impact, we aimed to comprehensively interconnect morphologic, immunologic and molecular data. METHODS: TCGA-defined molecular groups were determined by immunohistochemistry and sequencing in n = 142 endometrioid EC. WHO-defined histopathological grading was performed. The immunologic microenvironment (iTME) was characterised by the quantification of intraepithelial and stromal populations of tumor-infiltrating lymphocytes (TIL: overall T-cells; T-Killer cells; regulatory T-cells (Treg)). Immunologic parameters were correlated with WHO-grading, TCGA-subgroups and prognosis. RESULTS: High density TIL were significantly more frequent in high-grade (G3) compared to low-grade (G1/2) EC in the whole cohort and in the subgroup of POLE-wildtype-/microsatellite-stable-EC. MSI was associated with high-level TIL-infiltration when taking into account the type of mismatch repair defect (MLH1/PMS2; MSH2/MSH6). Prognostic impact of biomarkers depended on molecular subgroups: In p53-mutant EC, Treg were independently prognostic, in NSMP, the unique independently prognostic biomarker was WHO-grading. CONCLUSIONS: EC morphology and immunology differ depending on genetics. Our study delineated two molecularly distinct subgroups of immunogenic EC characterized by high-density TIL-infiltration: MSI EC and high-grade POLE-wildtype/microsatellite-stable-EC. Prognostic impact of TIL-populations relied on TCGA-subgroups indicating specific roles for TIL depending on molecular background. In NSMP, histopathological grading was the only prognostic biomarker demonstrating the relevance of WHO-grading in an era of molecular subtyping.
Authors: Brooke E Howitt; Sachet A Shukla; Lynette M Sholl; Lauren L Ritterhouse; Jaclyn C Watkins; Scott Rodig; Elizabeth Stover; Kyle C Strickland; Alan D D'Andrea; Catherine J Wu; Ursula A Matulonis; Panagiotis A Konstantinopoulos Journal: JAMA Oncol Date: 2015-12 Impact factor: 31.777
Authors: Aline Talhouk; Melissa K McConechy; Samuel Leung; Winnie Yang; Amy Lum; Janine Senz; Niki Boyd; Judith Pike; Michael Anglesio; Janice S Kwon; Anthony N Karnezis; David G Huntsman; C Blake Gilks; Jessica N McAlpine Journal: Cancer Date: 2017-01-06 Impact factor: 6.860
Authors: Ellen Stelloo; Remi A Nout; Elisabeth M Osse; Ina J Jürgenliemk-Schulz; Jan J Jobsen; Ludy C Lutgens; Elzbieta M van der Steen-Banasik; Hans W Nijman; Hein Putter; Tjalling Bosse; Carien L Creutzberg; Vincent T H B M Smit Journal: Clin Cancer Res Date: 2016-03-22 Impact factor: 12.531
Authors: A Talhouk; M K McConechy; S Leung; H H Li-Chang; J S Kwon; N Melnyk; W Yang; J Senz; N Boyd; A N Karnezis; D G Huntsman; C B Gilks; J N McAlpine Journal: Br J Cancer Date: 2015-06-30 Impact factor: 7.640
Authors: Robert A Soslow; Carmen Tornos; Kay J Park; Anais Malpica; Xavier Matias-Guiu; Esther Oliva; Vinita Parkash; Joseph Carlson; W Glenn McCluggage; C Blake Gilks Journal: Int J Gynecol Pathol Date: 2019-01 Impact factor: 2.762
Authors: Gunjan Mandal; Subir Biswas; Carmen M Anadon; Xiaoqing Yu; Chandler D Gatenbee; Sandhya Prabhakaran; Kyle K Payne; Ricardo A Chaurio; Alexandra Martin; Patrick Innamarato; Carlos Moran; John J Powers; Carly M Harro; Jessica A Mine; Kimberly B Sprenger; Kristen E Rigolizzo; Xuefeng Wang; Tyler J Curiel; Paulo C Rodriguez; Alexander R Anderson; Ozlen Saglam; Jose R Conejo-Garcia Journal: Cancer Res Date: 2022-03-01 Impact factor: 13.312
Authors: Hannah van der Woude; Kathryn Elizabeth Hally; Margaret Jane Currie; Olivier Gasser; Claire Elizabeth Henry Journal: Front Oncol Date: 2022-08-22 Impact factor: 5.738